Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1

View Full Paper
Ask AI
Bookmark
Share

Authors

CNChandramouli Nagarajan

Discussion

Loading...

Member takes

Overview

Phase I/II study demonstrates potential of mezigdomide and elranatamab in relapsed/refractory multiple myeloma, suggesting immune-modulatory benefits.

Key Points

  • To assess the safety, tolerability, and efficacy of mezigdomide in combination with elranatamab for patients with relapsed/refractory multiple myeloma.
  • Ongoing open-label single arm phase I/II study (MELT-MM) with an estimated enrollment of ~75 patients.
  • Phase I safety cohort to determine optimal recommended phase 2 dose (RP2D) and assess safety with doses of mezigdomide.
  • Elranatamab is administered according to a structured schedule for various cycles.
  • Among 11 enrolled patients, 90% achieved overall response rate (ORR), with 60% showing very good partial response (VGPR) or better, and 50% complete response (CR).
  • Cytokine release syndrome occurred in 54.5% of patients but was grade 1.
  • Initial results indicate combination of mezigdomide and elranatamab is feasible with therapeutic potential.

Cite This Study

Chandramouli Nagarajan (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d17ehttps://doi.org/10.1182/blood-2025-5835
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trial in progress: A phase 1b/2a study to evaluate mezigdomide in combination with elranatamab in patients with relapsed/refractory multiple myeloma2025
  2. 2Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study2025
  3. 3Real-world efficacy and safety of mezigdomide-dexamethasone in heavily pre-treatred multiple myeloma patients: An Italian case series2025 · 2 citations
  4. 4Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial2025 · 7 citations
  5. 5Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)2025